» Articles » PMID: 22960640

Targeting Mitochondrial Oxidative Metabolism As an Approach to Treat Heart Failure

Overview
Specialties Biochemistry
Biophysics
Date 2012 Sep 11
PMID 22960640
Citations 65
Authors
Affiliations
Soon will be listed here.
Abstract

Heart failure is a major cause of morbidity and mortality in the world. Cardiac energy metabolism, specifically fatty acid and glucose metabolism, is altered in heart failure and has been implicated as a contributing factor in the impaired heart function observed in heart failure patients. There is emerging evidence demonstrating that correcting these changes in energy metabolism by modulating mitochondrial oxidative metabolism may be an effective treatment for heart failure. Promising strategies include the downregulation of fatty acid oxidation and an increased coupling of glycolysis to glucose oxidation. Carnitine palmitoyl transferase I (CPT1), fatty acid β-oxidation enzymes, and pyruvate dehydrogenase kinase (PDK) are examples of metabolic targets for the treatment of heart failure. While targeting mitochondrial oxidative metabolism is a promising strategy to treat heart failure, further studies are needed to confirm the potential beneficial effect of modulating these metabolic targets as an approach to treating heart failure. This article is part of a Special Issue entitled: Cardiomyocyte Biology: Cardiac Pathways of Differentiation, Metabolism and Contraction.

Citing Articles

Recent advances associated with cardiometabolic remodeling in diabetes-induced heart failure.

Sharma G, Chaurasia S, Carlson M, Mishra P Am J Physiol Heart Circ Physiol. 2024; 327(6):H1327-H1342.

PMID: 39453429 PMC: 11684949. DOI: 10.1152/ajpheart.00539.2024.


The ketogenic diet does not improve cardiac function and blunts glucose oxidation in ischaemic heart failure.

Ho K, Karwi Q, Wang F, Wagg C, Zhang L, Panidarapu S Cardiovasc Res. 2024; 120(10):1126-1137.

PMID: 38691671 PMC: 11368127. DOI: 10.1093/cvr/cvae092.


KDM8 epigenetically controls cardiac metabolism to prevent initiation of dilated cardiomyopathy.

Ahmed A, Syed J, Chi L, Wang Y, Perez-Romero C, Lee D Nat Cardiovasc Res. 2024; 2(2):174-191.

PMID: 38665902 PMC: 11041705. DOI: 10.1038/s44161-023-00214-0.


Reduced mitochondrial pyruvate carrier expression in hearts with heart failure and reduced ejection fraction patients: ischemic vs. non-ischemic origin.

Lopez-Vazquez P, Fernandez-Caggiano M, Barge-Caballero E, Barge-Caballero G, Couto-Mallon D, Grille-Cancela Z Front Cardiovasc Med. 2024; 11:1349417.

PMID: 38525191 PMC: 10957580. DOI: 10.3389/fcvm.2024.1349417.


Mitochondrial transplantation: the advance to therapeutic application and molecular modulation.

McCully J, Del Nido P, Emani S Front Cardiovasc Med. 2024; 10:1268814.

PMID: 38162128 PMC: 10757322. DOI: 10.3389/fcvm.2023.1268814.